Kiora Pharmaceuticals (KPRX) Projected to Post Earnings on Friday

Kiora Pharmaceuticals (NASDAQ:KPRX) is expected to post its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect Kiora Pharmaceuticals to post earnings of ($0.72) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 7:00 AM ET.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its earnings results on Friday, August 8th. The company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.75 million. On average, analysts expect Kiora Pharmaceuticals to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kiora Pharmaceuticals Stock Down 0.9%

Shares of KPRX opened at $2.32 on Friday. The business’s fifty day moving average is $2.63 and its 200 day moving average is $2.86. Kiora Pharmaceuticals has a 12-month low of $2.21 and a 12-month high of $4.18. The stock has a market cap of $7.96 million, a P/E ratio of -0.80 and a beta of -0.70.

Wall Street Analyst Weigh In

A number of research firms have weighed in on KPRX. Zacks Research lowered shares of Kiora Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Kiora Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Friday, October 31st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.